Cybercrime is costing the world trillions every year - new report says victims lose an average of nearly $10,000 in every hit
THE SO WHAT
An average loss of nearly $10,000 per cyber incident reframes “minor” breaches as material line items for SMBs and mid-market firms. If you own P&L, treat basic security controls and incident response playbooks as cost containment, not overhead.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechWhy is Intel sharing its Atom CPU technology with a start-up? The answer could be in low-power x86 design
Licensing Atom to Rosaic — a Delaware startup with ex-Rivos talent and ties to Intel’s CEO — points to x86 being pushed down into ultra-low-power niches where Arm and RISC-V have been encroaching. If you build on x86, this is an early signal that you may get new low-power form factors without abandoning the ecosystem.
Deep & Emerging TechAustralia to Cut Price of Rooftop Solar for Factories, AFR Says
Cheaper rooftop solar for warehouses and factories in Australia turns power from a fixed utility line item into a capex lever for operators. If you run energy-intensive workloads or cold storage there, re-open your site selection and on-site generation models — payback periods just shortened.
Deep & Emerging TechWatch out — Microsoft login pages are being abused as hackers try and lure in unlucky victims, here's what to look out for
Attackers are bypassing passwords and MFA entirely by abusing Microsoft login flows to grab direct access to mail, files, Teams, SharePoint, and calendars across ~120 orgs. Treat OAuth consent and token scopes as production security surfaces this week—tighten conditional access, app consent policies, and session lifetimes.
Deep & Emerging TechLab Monkeys for $26,000 Show China’s Biotech Quest to Rival US
Primate prices spiking to $26,000 in China highlight a hard biological bottleneck in drug development and a growing dependence on cross-border animal supply chains. Biotech operators should expect higher trial costs and timelines — and more pressure to validate AI-first or in vitro alternatives earlier in the pipeline.